top of page
mcherry-NLRP3-ETO%252520100uM-30min-VP150-19_edited_edited_edited.jpg

RoNDBioCan

The adventure of this research project started in January 2018 and aim at discovering molecular mechanisms that direct the emergence and progression of lung cancer, along with the application of these findings for clinical treatment.

I am a Cancer Researcher based in Lyon, France. Since my PhD, my work is focused on understanding the early molecular alterations driving tumorigenesis. I am proud to be a Marie-Sklodowska Curie Fellow and I invite you to learn more about my work below.

Home: Welcome
IMG_3404_edited_edited.jpg

Bio

I’ve had a passion for science and research since I was a child, and my intensive studying and hard work finally paid off in 2010 when I graduated with a PhD in Molecular and Cellular Biology from the university of Lyon. I moved to San Diego in California to work as a PostDoc at Scripps Research in Dr Katja Lamia's Lab to study the molecular connection between the deregulation of our body clock  and the incidence on cancer development. I finally obtained a permanent position at the French National Institute of Health and medical Research (INSERM) in 2017 and moved back to Lyon. My journey led me to Dr Petrilli's group at the Cancer Research Center of Lyon to develop the RoNDBioCan project.  I enjoy delving into new fields of research and following the results of my experiments into the uncharted scientific territory. Learn more about my work by checking out my current projects and past publications.

Home: About Me

RoNDBioCan Research Project

The identification of new therapeutic strategies in the treatment of lung cancer is a research priority. Today 40% of these cancers remain of undetermined origin, so there is a crucial need to identify new mechanisms behind lung cancer. The action of current therapies relies mainly on the induction of highly toxic DNA lesions, where side-effects themselves lead to considerable morbidity and mortality. The MSCA project RoNDBioCan “Deciphering the Role of NLRP3 in the DNA Damage Response (DDR) pathway and evaluation of the potential predictive role of NLRP3 as a Biomarker in the treatment of lung Cancer” aims at understanding the molecular processes driving lung cancer.  
Tumors cells causes inflammation within a tissue. If the main role of inflammation is to participate in the elimination of tumors, multiple studies show that it also promotes their development. In our lab, we study an immune factor called NLRP3 involved in a protein complex called NLRP3 inflammasome. The aim of this complex is to secrete inflammatory cytokines involved in the immune response. Evidence has shown that NLRP3 is deregulated in a wide range of disorders, and its expression is systematically absent in lung cancer cells. Interestingly, our research group showed that NLRP3 is also an important factor for the response to DNA damage. Poor repair of these alterations could have insidious effects by causing the appearance of mutations, thus promoting the process of carcinogenesis. It is therefore crucial to better understand how the different functions of NLRP3 are regulated.
The objectives of this Marie Sklodowska Curie Action (MSCA) were to (1) decipher the molecular mechanism of NLRP3 function in the DDR pathway in non-tumoral and tumoral lung epithelial cells and to (2) evaluate the predictive role of NLRP3 expression in response to chemotherapy in the treatment of lung cancer. Another objective of the MSCA individual fellowship was to promote the development of the individual researcher and to sensitize a  public to MSCA.

 

Microscope

Role of NLRP3 in the DNA Damage Response pathway

Evidence has shown that NLRP3, an innate immune receptor, is systematically absent in NSCLC cells and is required for the activation of the DNA damage response pathway in response to DNA double strand breaks.
The objectives were to (1) decipher the molecular mechanism of NLRP3 function in the DDR pathway in non-malignant and malignant lung epithelial cells and to (2) evaluate the predictive role of NLRP3 expression in response to chemotherapy in the treatment of lung cancer.

Scientist in the Lab

NLRP3: At the interface of innate immunity and genome integrity

Inflammation and genomic instability are two main features of cancer development. Despite a great deal of research, we still have a very limited understanding to explain how our cells orchestrates proteins activities in our cells. 
Answering questions about this is essential for understanding the mechanistic role it plays on other inflammatory response or genotoxic stress response.

Home: Research

Contact Me

Cancer Research Center of Lyon
28 Rue Laennec 69003 Lyon France

  • Facebook
  • LinkedIn
Scientist on Tablet
Home: Contact
bottom of page